BioLife Solutions(BLFS)
icon
搜索文档
BioLife Solutions(BLFS) - 2023 Q2 - Earnings Call Transcript
2023-08-09 09:25
BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Chad Wiatrowski – TD Cowen Amanda Young – KeyBanc Capital Markets Thomas Flaten – Lake Street Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Second Quarter 2023 Shareholders and Analyst ...
BioLife Solutions(BLFS) - 2023 Q2 - Quarterly Report
2023-08-09 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ____________________________________________________ FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 ____________________________________________________ BioLife Solutions, Inc. (Exact na ...
BioLife Solutions(BLFS) - 2023 Q1 - Earnings Call Transcript
2023-05-11 09:30
分组1 - 公司正在探索战略替代方案,包括对Stirling ULT和Custom Biogenic Systems Cryogenic Freezer业务进行出许可、改变销售模式或出售等选择 [10][11][13] - 公司认为这些资产的资本密集型和较低利润的波动性销售周期业务,对公司的核心增长率和整体盈利能力没有带来预期的好处 [12] - 公司希望通过这次调整,将业务重点放在高毛利、高增长的经常性收入产品和服务上,提高公司的整体毛利率和EBITDA毛利率,并大幅减少营运资金的现金消耗 [14] 分组2 - 公司在第一季度继续获得新的细胞和基因疗法以及生物制药客户,推动细胞加工和存储以及存储服务平台的持续采用 [18] - 公司预计未来几个关键催化剂将支持增长,包括新的细胞和基因疗法获批、现有商业疗法在新地区或适应症获批、现有商业疗法作为一线或二线治疗获批,以及异基因疗法的发展 [22] - 公司的存储和存储服务平台在第一季度继续保持强劲增长,生物存储服务和evo冷链租赁业务均有新客户的增加 [23][24] 分组3 - 公司第一季度冷冻设备业务收入下滑,主要受到生物科技资本支出收紧和经济不确定性导致客户延迟采购决定的影响 [26][50] - 公司表示,即使在第一季度出现下滑,但根据目前的高置信度订单管道,有信心全年冷冻设备业务能够实现预期目标 [51] - 公司认为,如果最终决定出售冷冻设备业务,将有助于公司将重点放在高毛利、高增长的经常性收入业务上,提高整体盈利能力 [46][47] 问答环节重要的提问和回答 问题1 **Jacob Johnson 提问** 公司探索冷冻设备业务的战略替代方案,包括出售等选择,对公司未来的财务目标有何影响 [45][46] **Michael Rice 回答** 如果决定出售冷冻设备业务,公司将需要重新制定收入和盈利目标,因为这部分业务对整体盈利能力有重大影响 [46][47] 问题2 **Thomas Flaten 提问** 公司如何看待第一季度冷冻设备业务收入下滑的宏观因素,以及保持全年指引的原因 [50][51] **Michael Rice 回答** 公司有大量高置信度的冷冻设备订单预计在今年剩余时间内实现,这是公司维持全年指引的主要原因 [51] 问题3 **Paul Knight 提问** 公司是否会调整Sexton细胞加工产品和存储服务的销售方式,以应对冷冻设备业务的变化 [62][63] **Michael Rice 回答** 公司正在评估现有分销商的效率,并考虑其他分销渠道选择,包括如果决定出售冷冻设备业务,寻找更合适的分销渠道 [63][64]
BioLife Solutions(BLFS) - 2023 Q1 - Quarterly Report
2023-05-11 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3076866 (State or other jurisdiction of (IRS Em ...
BioLife Solutions(BLFS) - 2022 Q4 - Annual Report
2023-03-31 00:00
公司业务概况 - 公司是一家生命科学公司,开发和商业化用于生物材料制造、存储和运输的创新技术,并为生物和制药材料提供存储解决方案[152] - 公司目前的生产工具和服务组合包括三条收入线,包含七个主要产品:细胞处理、冷冻器和解冻系统、存储和存储服务[154] - 公司通过有机增长创新和收购机会,利用自身在低温生物学方面的专业知识,最大化产品平台的价值[155] 财务收入 - 公司主要通过产品销售、服务收入和租赁收入来实现收入[172] - 公司将收入分为产品收入、服务收入和租赁收入[173] - 2022年12月31日结束的年度,总收入为161,759千美元,比2021年增长36%[194] 成本和费用 - 2022年,总成本和运营费用为307,300千美元,比2021年增长99%[200] - 2022年,研发费用增加25%,达到14,798千美元[204] - 2022年,销售和营销费用增加54%,达到21,570千美元[207] 现金流和资金状况 - 截至2022年12月31日,现金及等价物为64.1百万美元,较2021年底减少[222] - 公司于2022年12月31日的经营活动现金流为负8,488,000美元,较2021年同期的负4,593,000美元增长85%[228] - 公司于2022年12月31日的投资活动现金流为负58,117,000美元,较2021年同期的负13,192,000美元增长341%[228] - 公司于2022年12月31日的融资活动现金流为16,316,000美元,较2021年同期的负2,778,000美元增长687%[228] 债务和资本需求 - 公司于2022年12月31日的长期债务总额为2560万美元,其中180万美元为短期债务[236] - 公司于2022年12月31日的租赁义务总额为1810万美元,其中300万美元为短期租赁[237] - 公司未来的资本需求将取决于多个因素,包括扩大细胞和基因治疗工具和服务业务、维持细胞和基因治疗产品和服务的产品收入和利润、实施额外的自动化生产设备、研发活动的范围和进展、以及任何拟议融资努力的成功[240]
BioLife Solutions (BLFS) Investor Presentation - Slideshow
2023-03-25 01:08
Analysts and Investors Day March 23, 2023 NASDAQ: BLFS Safe Harbor Statement Except for historical information contained herein, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning the expected financial performance of the company in 2023, 2024, and 2025 and our ability to meet our financial objectives during that time frame, including related to our expected ...
BioLife Solutions(BLFS) - 2022 Q4 - Earnings Call Transcript
2023-03-17 09:55
BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Yuan Zhi – B. Riley Thomas Flaten – Lake Street Operator Good day, and welcome to the BioLife Solutions’ Fourth Quarter 2022 and Full Year Earnings Call. Today’s call is being recorded. I would now like to turn the conference over to Troy Wichterman ...
BioLife Solutions(BLFS) - 2022 Q3 - Earnings Call Transcript
2022-11-10 11:08
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman & Chief Executive Officer Rod de Greef - President & Chief Operating Officer Conference Call Participants Paul Knight - KeyBanc Thomas Flaten - Lake Street Jacob Johnson - Stephens Stephanie Iannetta - Cowen and Company Yuan Zhi - B. Riley Securities Suraj Kalia - Oppenheimer Operator Good afternoon, ladies and gentlemen and th ...
BioLife Solutions(BLFS) - 2022 Q2 - Earnings Call Transcript
2022-08-10 09:40
BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman and Chief Executive Officer Rod de Greef - President and Chief Operating Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hannah Hefley - Stephens Max Masucci - Cowen and Company Suraj Kalia - Oppenheimer Operator Good day. My name is Chantel, and I'll be your conference operator today. At this tim ...
BioLife Solutions(BLFS) - 2022 Q1 - Earnings Call Transcript
2022-05-10 10:28
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial officer Mike Rice - Chairman and Chief Executive Officer Rod De Greef - President and Chief Operating Officer Conference Call Participants Max Masucci - Cowen and Company Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Suraj Kalia - Oppenheimer Operator Welcome to the BioLife Solutions First Quarter 2022 Financial Results Conference Ca ...